<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.107190</article-id><article-id pub-id-type="publisher-id">ACM-36439</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200700000_24825948.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  青岛大学附属医院COVID-19患者临床特点及治疗分析
  Clinical Characteristics and Treatment of COVID-19 Patients in the Affiliated Hospital of Qingdao University
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>登</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>芳芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>文成</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院呼吸与危重症医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>07</issue><fpage>1246</fpage><lpage>1251</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：2019年12月，新型冠状病毒肺炎疫情(Coronavirus Disease 2019)在中国爆发。本研究的目的是让临床医生更深入地了解这种新的传染病。方法：收集青岛大学附属医院收治的23例COVID-19患者的流行病学、临床特征、实验室检查、影像学特征、治疗及临床转归等资料进行分析。结果：共纳入23例COVID-19住院患者，中位年龄为43.0岁(IQR 31-57)，没有显著的性别差异(56.5%的女性)，大多数患者有武汉旅居史，大多数患者的胸部CT显示双侧斑片状影或磨玻璃样影。所有患者均接受了抗病毒治疗和糖皮质激素(8例[40%])。除1例死亡病例，1例患者还在住院外，21例患者均已出院，平均住院日为14.52天。结论：本文对23例COVID-19患者的临床特点及治疗方法进行了研究，目前尚无治疗COVID-19的有效抗病毒药物，应避免盲目或不恰当使用抗菌药物，仍需要进一步的临床试验来证实激素的临床益处。
    Objective: In December 2019, COVID-19 broke out in China. The purpose of this study is to provide clinicians with a better understanding of this new infectious disease. Methods: The data of epidemiology, clinical features, laboratory examination, imaging features, treatment and clinical outcomes of 23 patients admitted to the affiliated hospital of Qingdao university were collected and analyzed. Results: A total of 23 COVID-19 in patients were enrolled. The median age was 43.0 years (IQR 31-57), with no significant gender difference (56.5% of women). Most of the patients had a history of sojourn in Wuhan. Most patients have bilateral patchy or ground-glass images on chest CT. All patients received antiviral therapy and glucocorticoids (8 cases [40%]). In addition to one death and one patient in hospital, all 21 patients were discharged with an average length of stay of 14.52 days. Conclusion: In this study, the clinical characteristics and treatment of 23 COVID-19 patients were studied. Currently, there are no effective antiviral drugs for COVID-19. Blind or inappropriate use of antimicrobial drugs should be avoided. 
  
 
</p></abstract><kwd-group><kwd>COVID-19，临床特点，治疗, COVID-19</kwd><kwd> Clinical Characteristics</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>青岛大学附属医院COVID-19患者临床特点及治疗分析</title><p>潘登<sup>*</sup>，王芳芳，于文成<sup>#</sup></p><p>青岛大学附属医院呼吸与危重症医学科，山东 青岛</p><disp-formula id="hanspub.36439-formula10"><graphic xlink:href="//html.hanspub.org/file/16-1571404x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年6月5日；录用日期：2020年7月1日；发布日期：2020年7月8日</p><disp-formula id="hanspub.36439-formula11"><graphic xlink:href="//html.hanspub.org/file/16-1571404x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：2019年12月，新型冠状病毒肺炎疫情(Coronavirus Disease 2019)在中国爆发。本研究的目的是让临床医生更深入地了解这种新的传染病。方法：收集青岛大学附属医院收治的23例COVID-19患者的流行病学、临床特征、实验室检查、影像学特征、治疗及临床转归等资料进行分析。结果：共纳入23例COVID-19住院患者，中位年龄为43.0岁(IQR 31-57)，没有显著的性别差异(56.5%的女性)，大多数患者有武汉旅居史，大多数患者的胸部CT显示双侧斑片状影或磨玻璃样影。所有患者均接受了抗病毒治疗和糖皮质激素(8例[40%])。除1例死亡病例，1例患者还在住院外，21例患者均已出院，平均住院日为14.52天。结论：本文对23例COVID-19患者的临床特点及治疗方法进行了研究，目前尚无治疗COVID-19的有效抗病毒药物，应避免盲目或不恰当使用抗菌药物，仍需要进一步的临床试验来证实激素的临床益处。</p><p>关键词 :COVID-19，临床特点，治疗</p><disp-formula id="hanspub.36439-formula12"><graphic xlink:href="//html.hanspub.org/file/16-1571404x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/16-1571404x8_hanspub.png" /> <img src="//html.hanspub.org/file/16-1571404x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>2019年12月开始，中国武汉爆发了原因不明的肺炎病例。2020年1月7日，中国科学家从这些感染病毒的肺炎患者中分离出一种新型冠状病毒–严重急性呼吸综合征冠状病毒2 (SARS-CoV-2；以前称为2019-nCOV) [<xref ref-type="bibr" rid="hanspub.36439-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.36439-ref2">2</xref>]，该疾病后来于2020年2月被世卫组织定义为2019年冠状病毒病(COVID-19) [<xref ref-type="bibr" rid="hanspub.36439-ref3">3</xref>]。据报道，截至2020年4月1日，中国累计确诊82619例，其他国家累计确诊775932例。</p><p>本研究的目的是描述青岛大学附属医院收治的23例COVID-19患者的流行病学、临床特征、实验室检查、放射学特征、治疗和转归的特点。希望这些发现将有助于临床医生更清楚地了解和治疗这种新的传染病。</p></sec><sec id="s4"><title>2. 方法</title><sec id="s4_1"><title>2.1. 研究设计与参与者</title><p>23例患者均为山东省青岛市确诊病例，并于2020年1月22日至3月12日入住青岛大学附属医院，随后确诊为COVID-19。所有纳入本研究的COVID-19患者均根据WHO暂行指南进行诊断 [<xref ref-type="bibr" rid="hanspub.36439-ref4">4</xref>]，并由由传染病专家、呼吸内科医生、危重病医疗人员和急诊医学人员组成的多学科诊断和治疗(MDT)团队联合诊断。该研究已获得青岛大学附属医院伦理委员会的批准。</p></sec><sec id="s4_2"><title>2.2. 病例收集</title><p>收集自2020年1月22日在青岛发现的首例COVID-19患者的临床资料，至2020年3月12日共23例。研究小组使用电子病历系统(HIS)收集患者的临床资料。一般信息包括流行病学史、当前病史、症状、体征、实验室检查结果、胸部CT表现、治疗措施等。患者分为轻型(包括轻型和普通型)和重型(包括重症和危重症)组。轻度组临床症状轻微，影像学检查未见肺炎；普通组有发热、呼吸道症状，影像学表现为肺炎；重症组有呼吸窘迫，静息状态RR ≥ 30次/分钟，平均血氧饱和度 ≤ 93%，动脉血氧分压(PaO<sub>2</sub>)/氧浓度(FiO<sub>2</sub>) ≤ 300 mmHg；危重症组有呼吸衰竭和需要机械通气、休克的发生，以及其他需要重症监护病房(ICU)监测和治疗的器官的合并衰竭 [<xref ref-type="bibr" rid="hanspub.36439-ref5">5</xref>]。</p></sec><sec id="s4_3"><title>2.3. SARS-CoV-2病毒核酸检测</title><p>所有疑似病例均采用实时逆转录聚合酶链反应(real-time RT-PCR)检测，冠状病毒RNA阳性者为确诊病例。采集患者咽拭子标本，采用新型冠状病毒2019-nCoV核酸检测试剂盒检测COVID-19。</p></sec><sec id="s4_4"><title>2.4. 数据分析</title><p>分类变量被描述为频率和百分比，连续变量用平均值、中位数和四分位数范围(IQR)来描述。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>本研究纳入的分析指标主要包括性别，年龄，吸烟史，饮酒史，白细胞，淋巴细胞，血小板，中性粒细胞，血钙，PCT，CRP，LDH，D-二聚体，咳嗽，咳痰，腹泻，喘憋，体温 ≥ 38℃，CURB-65，CCI指数，基础疾病，影像学表现，临床治疗等。</p><p>治疗方面，有10例患者使用了奥司他韦(43.5%)，9例患者使用了阿比多尔(39.1%)，15例患者用了洛匹那韦利托那韦(克立芝) (65.2%)，5例患者使用了利巴韦林(21.7%)，5例患者使用了连花清瘟(21.7%)，8例患者使用了激素治疗(34.8%)，激素使用疗程为2~16天不等，联用阿比多尔和克立芝的患者有6例，平均住院日为20.1天，联用克立芝和利巴韦林的患者有4例，平均住院日为20.6天，3例患者使用了无创通气(13.0%)，1例患者使用了有创通气(4.3%)，除1例死亡病例，1例仍在住院外，其余21例患者均出院，平均住院日为14.52天。见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Statistics of relevant indicators in 23 patient</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >百分比</th><th align="center" valign="middle" >百分比</th><th align="center" valign="middle" >百分比</th><th align="center" valign="middle" >百分比</th></tr></thead><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >男(43.5%)</td><td align="center" valign="middle" >女(56.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" >有(4.3%)</td><td align="center" valign="middle" >无(95.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >饮酒史</td><td align="center" valign="middle" >有(17.4%)</td><td align="center" valign="middle" >无(82.6%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >白细胞</td><td align="center" valign="middle" >↓ (21.7%)</td><td align="center" valign="middle" >↑ (4.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴细胞</td><td align="center" valign="middle" >↓ (47.8%)</td><td align="center" valign="middle" >↑ (8.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血小板</td><td align="center" valign="middle" >↓ (13.0%)</td><td align="center" valign="middle" >↑ (4.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中性粒细胞</td><td align="center" valign="middle" >↓ (21.7%)</td><td align="center" valign="middle" >↑ (4.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >LDH</td><td align="center" valign="middle" >↓ (4.3%)</td><td align="center" valign="middle" >↑ (39.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >D-二聚体</td><td align="center" valign="middle" >↓ (0.0%)</td><td align="center" valign="middle" >↑ (34.8%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >纤维蛋白原</td><td align="center" valign="middle" >↓ (0.0%)</td><td align="center" valign="middle" >↑ (43.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CRP</td><td align="center" valign="middle" >↓ (0.0%)</td><td align="center" valign="middle" >↑ (65.2%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血钙</td><td align="center" valign="middle" >↓ (39.1%)</td><td align="center" valign="middle" >↑ (8.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >CURB-65</td><td align="center" valign="middle" >0分(82.6%)</td><td align="center" valign="middle" >2分(4.3%)</td><td align="center" valign="middle" >3分(13.0%)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >CCI指数</th><th align="center" valign="middle" >0 (78.3%)</th><th align="center" valign="middle" >1 (8.7%)</th><th align="center" valign="middle" >2 (4.3%)</th><th align="center" valign="middle" >3 (8.7%)</th></tr></thead><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >有(13.0%)</td><td align="center" valign="middle" >无(87.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >冠心病</td><td align="center" valign="middle" >有(13.0%)</td><td align="center" valign="middle" >无(87.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >有(13.0%)</td><td align="center" valign="middle" >无(87.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >咳嗽</td><td align="center" valign="middle" >有(34.8%)</td><td align="center" valign="middle" >无(65.2%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >咳痰</td><td align="center" valign="middle" >有(21.7%)</td><td align="center" valign="middle" >无(78.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >腹泻 喘憋 体温≥38℃</td><td align="center" valign="middle" >有(17.4%) 有(8.7%) 有(56.5%)</td><td align="center" valign="middle" >无(82.6%) 无(91.3%) 无(43.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >双肺</td><td align="center" valign="middle" >有(78.3%)</td><td align="center" valign="middle" >无(21.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >纤维化</td><td align="center" valign="middle" >有(8.7%)</td><td align="center" valign="middle" >无(91.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >斑片状</td><td align="center" valign="middle" >有(73.9%)</td><td align="center" valign="middle" >无(26.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >磨玻璃影</td><td align="center" valign="middle" >有(60.9%)</td><td align="center" valign="middle" >无(39.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 23例病人相关指标的统计</p></sec><sec id="s6"><title>4. 讨论</title><p>该报告是针对2020年1月22日至3月12日入住青岛大学附属医院的新冠肺炎患者，研究显示男女患者的比例没有显著差异，大多数患者有武汉旅居史，或与武汉人有接触，再次验证了人传人的结论 [<xref ref-type="bibr" rid="hanspub.36439-ref6">6</xref>]。主要症状为发热、咳嗽 [<xref ref-type="bibr" rid="hanspub.36439-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.36439-ref8">8</xref>]。其他症状包括咳痰、腹泻等。住院期间的主要并发症包括ARDS、心律失常和休克。双肺斑片状影和磨玻璃影是典型的COVID-19的CT表现。</p><p>23例患者中，仅1例死亡，本例将简要讨论。她是一名90岁的女性，长期卧床，冠心病史10余年，糖尿病史2年，自服“二甲双胍、格列美脲”，血糖控制尚可，因其陪护1天前确诊“新型冠状病毒肺炎(普通型)”，该病人筛查病毒核酸检测呈阳性，确诊为“新型冠状病毒肺炎”。PCT、CRP、LDH、D-二聚体和纤维蛋白原均高于正常水平；淋巴细胞和血小板均低于正常水平；白细胞、中性粒细胞和血Ca均正常；CURB-65评分为3，CCI指数为1。曹彬教授团队研究发现特别是老年人，D-二聚体水平大于1 μg/L，SOFA评分高等与住院后死亡有很大关联。此外，血IL-6水平升高、高敏感性心肌肌钙蛋白I、LDH和淋巴细胞减少在严重的COVID-19疾病中更为常见。</p><p>目前，在中国还没有针对COVID-19的特效治疗药物。控制该病的主要措施是早期诊断、隔离治疗和对患者的支持治疗。目前尚无有效的抗病毒药物。WHO根据现有的研究证据列出如下候选抗病毒药物，包括瑞德西韦、洛匹那韦/利托那韦单药或联合干扰素等；轻型及普通型COVID-19患者不建议使用抗菌药物，重型及危重型患者如评估存在合并或继发细菌、真菌感染时可使用抗菌药物治疗，COVID-19患者不合理使用抗菌药物，会增加院内耐药细菌感染的风险，此外重型或危重型患者早期淋巴细胞下降，部分患者较大剂量使用糖皮质激素，入住ICU，接受无创或有创机械通气等抢救措施，都是继发侵袭性真菌感染的高危因素 [<xref ref-type="bibr" rid="hanspub.36439-ref9">9</xref>]。</p><p>在SARS-CoV和MERS-CoV爆发期间，糖皮质激素被广泛使用，而在COVID-19中的应用由于没有RCT研究证据，具有争议。急性肺损伤和ARDS在一定程度上是由宿主免疫反应引起的。糖皮质激素能抑制肺部炎症反应，但同时也能抑制免疫反应和病原体清除。COVID-19需要进一步的临床试验来证实糖皮质激素的临床益处。最近的临床研究建议，糖皮质激素不应用于治疗由COVID-19引起的肺损伤或休克 [<xref ref-type="bibr" rid="hanspub.36439-ref10">10</xref>]。然而，一些研究表明，合理使用糖皮质激素可以降低危重患者的死亡率，缩短住院时间，不引起继发性感染等并发症 [<xref ref-type="bibr" rid="hanspub.36439-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.36439-ref12">12</xref>]。因此，建议按照中国胸科学会发布的《2019年糖皮质激素治疗冠状病毒病的应用建议：糖皮质激素用于新型冠状病毒肺炎的建议》中建议使用糖皮质激素治疗 [<xref ref-type="bibr" rid="hanspub.36439-ref13">13</xref>]。一般来说，直到2002年和2003年在中国广东爆发SARS，冠状病毒才被认为对人类具有高致病性。另一种高致病性冠状病毒，中东呼吸综合征(MERS)冠状病毒于2012年在中东国家出现 [<xref ref-type="bibr" rid="hanspub.36439-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.36439-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.36439-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.36439-ref17">17</xref>]。新冠肺炎是非常突然和具有破坏性的，尽管死亡率低于3% [<xref ref-type="bibr" rid="hanspub.36439-ref18">18</xref>]，而SARS-CoV死亡率为9.6%，MERS-CoV死亡率为34% [<xref ref-type="bibr" rid="hanspub.36439-ref19">19</xref>]。2019年12月湖北武汉爆发COVID-19以来，冠状病毒对人们的健康和生活产生了重大影响。它已经迅速扩展到中国34个省级部门 [<xref ref-type="bibr" rid="hanspub.36439-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.36439-ref21">21</xref>]。SARS-CoV-2感染的临床范围似乎很广泛，包括无症状感染、轻度上呼吸道疾病、严重病毒性肺炎伴呼吸衰竭甚至死亡 [<xref ref-type="bibr" rid="hanspub.36439-ref22">22</xref>]。冠状病毒核酸可在咽喉、痰液、下呼吸道分泌物和血液中检出 [<xref ref-type="bibr" rid="hanspub.36439-ref23">23</xref>]。23例病人均在早期使用了抗病毒治疗，其中有8例患者使用了激素治疗，疗程在2~16天不等。</p><p>这项研究有几个局限性。首先，与武汉市相比，样本量相对较小，这可能对统计结果有一定影响。第二，23例患者只是青岛大学附属医院收治的，青岛地区还有其他定点医院，所以样本代表不了青岛市的病例特点。其次，重症患者仅有1例，所以无法按照轻型重型来对患者进行分组。</p><p>在未来的研究中，将建立多中心研究来扩大样本量，并进行更严格的随机对照试验。此外，还将对痊愈出院的患者进行随访。</p></sec><sec id="s7"><title>文章引用</title><p>潘 登,王芳芳,于文成. 青岛大学附属医院COVID-19患者临床特点及治疗分析Clinical Characteristics and Treatment of COVID-19 Patients in the Affiliated Hospital of Qingdao University[J]. 临床医学进展, 2020, 10(07): 1246-1251. https://doi.org/10.12677/ACM.2020.107190</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36439-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Phelan, A.L., Katz, R. and Gostin, L.O. (2020) The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA, 323, 709-710. &lt;br&gt;https://doi.org/10.1001/jama.2020.1097</mixed-citation></ref><ref id="hanspub.36439-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gorbalenya, A.E., Baker, S.C., Baric, R.S., et al. (2020) Severe Acute Respiratory Syndrome-Related Coronavirus: The Species and Its Viruses—A Statement of the Coronavirus Study Group. bioRxiv.  
&lt;br&gt;https://doi.org/10.1101/2020.02.07.937862</mixed-citation></ref><ref id="hanspub.36439-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chan, J.W.M., Ng, C.K., Chan, Y.H., et al. (2003) Short Term Outcome and Risk Factors for Adverse Clinical Outcomes in Adults with Severe Acute Respiratory Syndrome (SARS). Thorax, 58, 686-689.  
&lt;br&gt;https://doi.org/10.1136/thorax.58.8.686</mixed-citation></ref><ref id="hanspub.36439-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2020) Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (2019-nCoV) Infection Is Suspected: Interim Guidance, 28 January 2020. World Health Organization, Geneva.</mixed-citation></ref><ref id="hanspub.36439-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Diagnosis and Treatment of Novel Coronavirus Pneumonia (Trial Version Fifth). Chinese Journal of Integrated Traditional and Western Medicine, 1-3. http://kns.cnki.net/kcms/detail/11.2787.R.20200208.1034.002.html</mixed-citation></ref><ref id="hanspub.36439-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Phan, L.T., Nguyen, T.V., Luong, Q.C., Nguyen, T.V., Nguyen, H.T., Le, H.Q., et al. (2020) Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. New England Journal of Medicine, 382, 872-874.  
&lt;br&gt;https://doi.org/10.1056/NEJMc2001272</mixed-citation></ref><ref id="hanspub.36439-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA, 323, 1061-1069.  
&lt;br&gt;https://doi.org/10.1001/jama.2020.1585</mixed-citation></ref><ref id="hanspub.36439-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yu, P., Zhu, J., Zhang, Z., Han, Y. and Huang, L. (2020) A Familial Cluster of Infection Associated with the 2019 Novel Coronavirus Indicating Potential Person-to-Person Transmission during the Incubation Period. The Journal of Infectious Diseases, 221, 1757-1761. &lt;br&gt;https://doi.org/10.1093/infdis/jiaa077</mixed-citation></ref><ref id="hanspub.36439-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">余进, 刘伟, 陈伟, 等. 关于重症新型冠状病毒肺炎继发侵袭性真菌感染实验室诊治建议[J]. 中国真菌学杂志, 2020, 15(1): 1-5.</mixed-citation></ref><ref id="hanspub.36439-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Shang, L., Zhao, J., Hu, Y., Du, R. and Cao, B. (2020) On the USE of corticosteroids for 2019-nCoV Pneumonia. The Lancet, 395, 683-684. &lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30361-5</mixed-citation></ref><ref id="hanspub.36439-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Stockman, L.J., Bellamy, R. and Garner, P. (2006) SARS: Systematic Review of Treatment Effects. PLoS Medicine, 3, e343. &lt;br&gt;https://doi.org/10.1371/journal.pmed.0030343</mixed-citation></ref><ref id="hanspub.36439-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chen, R.-C., Tang, X.-P., Tan, S.-Y., Liang, B.-L., Wan, Z.-Y., Fang, J.-Q., et al. (2006) Treatment of Severe Acute Respiratory Syndrome with Glucosteroids: The Guangzhou Experience. Chest, 129, 1441-1452.  
&lt;br&gt;https://doi.org/10.1378/chest.129.6.1441</mixed-citation></ref><ref id="hanspub.36439-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, J., Hu, Y., Du, R., Chen, Z., Jin, Y., Zhou, M., et al. (2020) Expert Consensus on the Use of Corticosteroid in Patients with 2019-nCoV Pneumonia. Chinese Journal of Tuberculosis and Respiratory Diseases, 43, E007.</mixed-citation></ref><ref id="hanspub.36439-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A.., et al. (2003) Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. The New England Journal of Medicine, 348, 1967-1976. &lt;br&gt;https://doi.org/10.1056/NEJMoa030747</mixed-citation></ref><ref id="hanspub.36439-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J.A., Lim, W., et al. (2003) A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. The New England Journal of Medicine, 348, 1953-1966. &lt;br&gt;https://doi.org/10.1056/NEJMoa030781</mixed-citation></ref><ref id="hanspub.36439-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D. and Fouchier, R.A. (2012) Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. The New England Journal of Medicine, 367, 1814-1820.  
&lt;br&gt;https://doi.org/10.1056/NEJMoa1211721</mixed-citation></ref><ref id="hanspub.36439-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhong, N.S., Zheng, B.J., Li, Y.M., Poon, L.L.M., Xie, Z.H., Chan, K.H., Li, P.H., Tan, S.Y., Chang, Q., Xie, J.P., et al. (2003) Epidemiology and Cause of Severe Acute Respiratory Syndrome (Sars) in Guangdong, People’s Republic of China, in February, 2003. Lancet (Lond. Engl.), 362, 1353-1358. &lt;br&gt;https://doi.org/10.1016/S0140-6736(03)14630-2</mixed-citation></ref><ref id="hanspub.36439-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kui, L., Fang, Y.Y., Deng, Y., Liu, W., Wang, M.F., Ma, J.P., et al. (2020) Clinical Characteristics of Novel Coronavirus Cases in Tertiary Hospitals in Hubei Province. Chinese Medical Journal.</mixed-citation></ref><ref id="hanspub.36439-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, X., Rayner, S. and Luo, M.-H. (2020) Does SARS-CoV-2 Have a Longer Incubation Period than SARS and MERS? Journal of Medical Virology, 92, 476-478. &lt;br&gt;https://doi.org/10.1002/jmv.25708</mixed-citation></ref><ref id="hanspub.36439-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Lu, H., Stratton, C.W. and Tang, Y.W. (2020) Outbreak of Pneumonia of Unknown Etiology in Wuhan China: The Mystery and the Miracle. Journal of Medical Virology, 92, 401-402. &lt;br&gt;https://doi.org/10.1002/jmv.25678</mixed-citation></ref><ref id="hanspub.36439-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Hui, D.S., Azhar, E.I., Madani, T.A., et al. (2020) The Continuing COVID-19 Epidemic Threat of Novel Coronaviruses to Global Health—The Latest 2019 Novel Coronavirus Outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264-266. &lt;br&gt;https://doi.org/10.1016/j.ijid.2020.01.009</mixed-citation></ref><ref id="hanspub.36439-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C., Wang, Y., Li, X., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet, 395, 497-506. &lt;br&gt;https://doi.org/10.1016/S0140-6736(20)30183-5</mixed-citation></ref><ref id="hanspub.36439-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y.S., Peng, F.J., Wang, R.S., Guan, K., Jiang, T.J., Xu, G.G., Sun, J. and Chang, C. (2020) The Deadly Coronaviruses: The 2003 SARS Pandemic and the 2020 Novel Coronavirus Epidemic in China. Journal of Autoimmunity, 109, 102434.</mixed-citation></ref></ref-list></back></article>